Factors underlying metabolic phenotypes, such as the metabolically healthy but obese phenotype, remain unclear. Differences in metabolic phenotypes-particularly, among individuals with a similar body mass index-could be related to concentrations of persistent organic pollutants (POPs). To our knowledge, no studies have analyzed POPs and metabolic phenotypes in normal-weight persons. We investigated the relationships between serum concentrations of POPs and metabolic phenotypes in 860 normal-weight, overweight, and obese participants in the 2002 Catalan Health Interview Survey (Spain). POP concentrations were significantly higher in metabolically unhealthy than in metabolically healthy individuals. In models adjusting for body mass index and other confounders, hexachlorobenzene, β-hexachlorocyclohexane, and polychlorinated biphenyls were associated with the unhealthy metabolic phenotype and metabolic syndrome. Among normal-weight individuals, the adjusted prevalence ratio of having an unhealthy phenotype for the upper category of the sum of orders of the 6 mentioned POPs (all individually associated with metabolic phenotypes) was 4.1 (95% confidence interval: 1.7, 10.0). Among overweight and obese individuals, the corresponding prevalence ratio for the sum of polychlorinated biphenyls was 1.4 (95% confidence interval: 1.0, 1.8). Our results supported the hypothesis that POP concentrations are associated with unhealthy metabolic phenotypes, not only in obese and overweight individuals but also (and probably more strongly) in normal-weight individuals.
Recent studies have revealed factors that appear to protect obese individuals from cardiometabolic disturbances (1, 2) . Such studies used body size-metabolic phenotypes to classify individuals according to body mass index (BMI) and the presence or absence of cardiometabolic complications including hypertension, dyslipidemia, or insulin resistance. One such phenotype, "metabolically healthy obese," consists of individuals who remain free of metabolic abnormalities despite being obese. Another metabolic phenotype comprises normalweight but metabolically unhealthy individuals (i.e., individuals who present cardiometabolic abnormalities despite having a normal BMI), also called "metabolically obese nonobese" (MONO) (3) . Some studies found factors such as visceral fat accumulation, adipose cell size, and behavioral characteristics (such as physical activity and alcohol intake) to be related to metabolic phenotypes (1, (4) (5) (6) . However, it remains unclear what underlying factors and mechanisms explain the normal metabolic profile of metabolically healthy, obese individuals (1, 2) .
Similar to metabolically healthy obesity, the understanding of the MONO individual is important because an abnormal metabolic profile, rather than adiposity itself, is associated with a higher risk for cardiovascular diseases (7) . While regional fat distribution and body composition could partly explain differences in the metabolic profile among nonobese individuals (8) , some environmental contaminants, such as persistent organic pollutants (POPs), might also play a role, as they probably do in obese individuals (9, 10) .
POPs are synthetic chemicals highly lipophilic and resistant to degradation; virtually all humans accumulate POP mixtures throughout the life course, with wide interindividual differences in concentrations (10) (11) (12) . Most POPs are endocrine disruptors (13) , and several prospective studies have reported positive relationships between POP concentrations and type 2 diabetes, insulin resistance, hypertension, and other cardiometabolic disorders (9, 10, 12, (14) (15) (16) (17) . Additionally, other studies have reported positive associations between POPs and metabolic syndrome (MetS) (18) (19) (20) (21) . Therefore, differences among metabolic phenotypes-which take into account not only the components of MetS but also such other factors as insulin resistance and biomarkers of inflammation-could be related to differences in POP concentrations.
To our knowledge, only 2 previous studies have analyzed the association between POPs and metabolic phenotypes. One study was performed in 76 nondiabetic, obese postmenopausal women (22) , and the other selected 184 overweight and obese patients visiting a weight-management clinic (23) . It appears that no studies have analyzed POPs and unhealthy metabolic phenotypes in normal-weight persons. We analyzed, for the first time, the relationship between body POP concentrations and metabolic phenotypes in a sample of the general population (n = 860). Our sample included: 1) men and women; 2) a wide range of ages (18-74 years); 3) normal-weight, overweight, and obese individuals; and 4) diabetic and nondiabetic individuals. Of potential importance, Catalonia (in Spain) is a Mediterranean region with dietary patterns generally protective against several cardiometabolic risk factors (24) .
The aim of the present study was to analyze the relationship between POP serum concentrations and metabolic phenotypes in normal-weight, overweight, and obese individuals in the general adult population of Catalonia, Spain. Additionally, we analyzed the relationship between POPs and MetS.
METHODS

Study population
The study population has been described in detail elsewhere (25, 26) . Briefly, participants in the Catalan Health Interview Survey, aged 18-74 years, were offered the option to take part in a health examination that included a physical examination, a supplementary interview, and the collection of urine and blood samples. A total of 1,374 individuals, who gave specific written informed consent, participated during 2002 in the health examination (27) .
Trained nurses recorded the weight and height; the corresponding BMI was computed (measured weight (kg) divided by measured height squared (m 2 )) and grouped into 4 categories: underweight (<18.50), normal weight (18.50-24.99), overweight (25.00-29.99), and obese (≥30.00). Waist circumference was measured at the level of the umbilicus. Systolic and diastolic blood pressures were measured twice, and the average was used in the statistical analyses. Blood samples were drawn after 12 hours of fasting (27) . A capillary blood sample was also obtained during the health examination and used to determine glucose concentration in whole blood (26) . Information on blood concentrations of lipids and at least 1 mL of serum (for POP analyses) was available for 919 participants.
Ten underweight participants were excluded from the statistical analyses. In the present report, analyses of metabolic phenotypes were based on 860 participants with data available on POP serum concentrations and on metabolic phenotype. There were no statistically significant differences between the 860 individuals and the remaining participants in the health examination with respect to age, sex, BMI, educational level, or occupational social class. Analyses of MetS were based on 858 and 881 participants with information on MetS status according to the definitions of the International Diabetes Federation (IDF) (28) and the National Cholesterol Education Program-Third Adult Treatment Panel (ATPIII) (29) , respectively.
Body size-metabolic phenotypes
Body size-metabolic phenotypes were defined using criteria previously described by Wildman et al. (6) . Individuals were classified as having an unhealthy metabolic phenotype if they had 2 or more of the following cardiometabolic abnormalities: hypertension (systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or current use of antihypertensive medication); hypertriglyceridemia (fasting triglyceride level ≥150 mg/dL; no information on triglyceride-lowering medication was available); low high-density lipoprotein (HDL) cholesterol (<40 mg/dL in men, <50 mg/dL in women, or current use of cholesterol-lowering medication); hyperglycemia (fasting glucose level ≥100 mg/dL, current use of insulin or oral antidiabetic medication, or previous diagnosis of diabetes); insulin resistance (homeostatic model assessment of insulin resistance of >4.66, the 90th percentile); and systemic inflammation (high-sensitivity C-reactive protein level of >7.35 mg/L, the 90th percentile). Distributions are shown in Table 1 .
Metabolic syndrome
MetS status was assigned to participants following the IDF and ATPIII definitions. According to IDF (28) , participants were considered to have MetS if they had abdominal obesity (waist circumference of ≥94 cm for men or ≥80 cm for women) and also 2 or more of the following cardiometabolic abnormalities (as previously defined): hypertriglyceridemia, low HDL cholesterol, hypertension, or hyperglycemia. According to the ATPIII definition (29) , participants were considered to have MetS if they had 3 or more of these 5 components: abdominal obesity (waist circumference of ≥102 cm for men or ≥88 cm for women), hypertriglyceridemia, low HDL cholesterol, hypertension, or hyperglycemia (fasting glucose level of ≥100 mg/dL or current use of insulin or oral antidiabetic medication).
https://academic.oup.com/aje)). Serum concentrations of 19 POPs were analyzed by gas chromatography with electroncapture detection. Main statistical analyses were limited to the 8 compounds that were above the detection limit in >85% of participants: p,p′-dichlorodiphenyltrichloroethane (DDT); p,p′-dichlorodiphenyldichloroethene (DDE); polychlorinated biphenyl (PCB) congeners 118, 138, 153, and 180; hexachlorobenzene (HCB); and β-hexachlorocyclohexane (HCH) (25) . Lipid correction (division of individual crude serum POP concentrations by total lipids) is not appropriate when studying metabolic phenotypes (10, 30, 31) , and thus in the present study POP concentrations are expressed in nanograms per milliliter (ng/mL).
Clinical bioassays. Cholesterol and triglycerides were determined enzymatically (Roche Diagnostics, Basel, Switzerland) in serum obtained in the health examination (25, 27) . Serum concentrations of high-sensitivity C-reactive protein were measured with a high-sensitivity turbidimetric assay (Quantex CRP Ultra Sensitive; Biokit SA, Barcelona, Spain) (32) . Fasting insulin was determined by radioimmunoassay, using commercial kits (Amersham, Little Chalfont, United Kingdom), and the homeostasis model assessment was used to calculate insulin resistance applying the following formula: (fasting insulin (mU/L) × fasting glucose (mg/dL) × 0.0555)/22.5 (33) .
Statistical analyses
Univariate statistics were computed as customary (34) . Fisher's exact test for homogeneity was applied to assess the relationship between 2 categorical variables. To assess differences on age, BMI, and POP concentrations according to metabolic phenotype and MetS status, Student's t test and the Mann-Whitney U test were used.
To estimate the magnitude of the associations between POPs and an unhealthy metabolic phenotype (≥2 cardiometabolic abnormalities), prevalence ratios and their 95% confidence intervals were computed by Poisson regression models with robust variance (35) . Statistically significant interactions were found between BMI and POP concentrations (P for interaction ≤0.005 for all); thus, analyses were stratified by BMI (dichotomized as normal-weight and overweight/obese). Prevalence ratios were also estimated from logistic models as the ratio of the predicted probabilities for each outcome comparing the 3 highest quartiles with the lowest one, and 95% confidence intervals were generated by the bootstrap percentile method using 1,000 resamples (36) . Prevalence ratios were also computed by Poisson regression to estimate the magnitude of the associations between POPs and MetS.
POP concentrations were entered in the models as quartile categories. To assess exposure to multiple compounds, we f Defined as ≥100 mg/dL or medication use; we excluded 7 subjects missing blood-glucose concentrations, 6 subjects with blood-glucose concentration ≤60 mg/dL, 16 nonfasting subjects with blood-glucose concentration ≥100 mg/dL and no medication use, and 4 pregnant women.
g Defined as above the 90th percentile (4.66); we excluded 43 subjects reporting a current use of insulin or oral antidiabetic medication, 32 nonfasting subjects, 7 subjects missing blood glucose concentrations, 5 subjects with blood glucose concentration ≤60 mg/dL, and 4 pregnant women.
h Defined as above the 90th percentile (7.35 mg/L).
computed the sum of PCBs, the sum of orders of the 8 most prevalent POPs mentioned, and the sum of orders of the 6 POPs individually associated with metabolic phenotypes (11, 26 ) (see Web Appendix).
In models with adjustments, the following potential confounders were included: age, sex, BMI, cigarette smoking, alcohol consumption, physical activity, occupational social class, and educational level. We assessed linear dose-response relationships through the multivariate analogue of Mantel's extension test for linear trend; when a linear trend was not apparent, the probability test was used.
General linear regression models were used to assess the relationship between number of cardiometabolic abnormalities (as a continuous variable, instead of the binary outcome "healthy / unhealthy metabolic phenotype," Table 1 ) and concentrations of POPs. Results are expressed as adjusted geometric means with their corresponding 95% confidence intervals (34) .
The level of statistical significance was set at 0.05 and all tests were 2-tailed. Analyses were conducted using SPSS, version 22.0.0 (SPSS Inc., Chicago, Illinois), and R, version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
The prevalence of the metabolically healthy phenotype in the study population was 56.2% (Table 1) . Of the 860 participants, 39 (4.5%) were obese yet metabolically healthy, 151 (17.6%) were overweight yet metabolically healthy, and 71 (8.3%) had normal weight but were metabolically unhealthy (≥2 cardiometabolic abnormalities; i.e., MONO). The percentages of individuals with a healthy metabolic phenotype among overweight and obese participants were 46.5 and 22.8, respectively, whereas 19.5% of the normal-weight participants were metabolically unhealthy (Table 1) .
Among both normal-weight participants and overweight/ obese participants, individuals with an unhealthy metabolic phenotype were older and had a higher BMI and higher waist circumference than individuals with a healthy metabolic phenotype ( Table 2) . Concentrations of all POPs were significantly higher in metabolically unhealthy individuals than in metabolically healthy subjects ( Figure 1 and Web Table 1 ). For example, among normal-weight individuals, the median concentration of HCB and PCB 118 was 2 times higher in metabolically unhealthy individuals than in metabolically healthy subjects. The corresponding values among overweight and obese individuals were 1.8 and 1.7 for HCB and PCB 118, respectively (P < 0.001). The differences in POP concentrations between metabolically healthy and unhealthy individuals (Figure 1) show patterns strikingly similar among normal-weight and overweight/obese participants.
Among normal-weight individuals, multivariate analyses showed that concentrations of all 4 PCBs were positively associated with having an unhealthy (vs. healthy) metabolic phenotype-the so-called MONO-after adjusting for age, sex, BMI, cigarette smoking, alcohol consumption, and physical activity, in a nonlinear dose-response manner. Prevalence ratios for the upper quartile of PCBs ranged between 1.1 and 1.9, whereas prevalence ratios for the third quartile ranged between 2.5 and 3.2 (P values <0.01) ( Table 3 , model 1). When the sum of PCBs was considered, normal-weight individuals in the third quartile had 3 times the risk of having an unhealthy metabolic phenotype compared with individuals in the lowest quartile of the sum of PCBs (95% confidence interval (CI): 1.4, 6.3) (P ≤ 0.001). HCB and β-HCH were also significantly associated with having an unhealthy metabolic phenotype, in this case in a linear dose-response manner; prevalence ratios for the upper quartile of HCB and β-HCH were 2.0 (95% CI: 0.8, 4.9) and 2.4 (95% CI: 1.0, 5.9), respectively (P for linear trend < 0.1) ( Table 3 , model 1). Among normal-weight individuals, the unhealthy metabolic phenotype was also associated with mixtures of POPs: Individuals in the upper category of the sum of orders of the 6 mentioned POPs had 3.7 times the risk of having an unhealthy metabolic phenotype compared with subjects in the lowest category. The prevalence ratios for the second and third categories were 2.6 and 3.0, respectively (P trend = 0.003). Associations were also found between the sum of orders of all 8 POPs and the unhealthy phenotype (prevalence ratios for the second, third, and fourth categories = 2.4, 2.9, and 3.0, respectively; P trend = 0.008). When model 1 further adjusted for occupational social class (Table 3 , model 2), all above-mentioned associations remained statistically significant and the magnitude of the prevalence ratios increased slightly (e.g., the prevalence ratio for the third quartile of PCB 180 became 3.6 (95% CI: 1.6, 7.9)). Adding adjustment for education to model 1 did not materially change the estimates.
Among overweight and obese individuals, models with adjustments showed that individuals with concentrations of PCBs in the upper quartile were more likely to have an unhealthy metabolic phenotype than individuals in the lower quartile. Prevalence ratios for individuals in the upper quartile of PCBs ranged between 1.2 and 1.4 (P for trend <0.005 for all) (Table 4 , model 1). For HCB this prevalence ratio was also 1.4 (95% CI: 1.0, 1.9) (P = 0.023). The unhealthy metabolic phenotype was also associated with the sum of orders of the 6 mentioned POPs and with the sum of orders of all 8 POPs: The prevalence ratio of having an unhealthy phenotype for individuals in the each upper category was 1.2 (95% CI: 0.9, 1.7 and P ≤ 0.020 for both) (Table 4 , model 1). Further adjusting for occupational social class (Table 4 , model 2) or for education did not materially change the estimates. No significant interactions were observed between POP concentrations and sex or age in overweight/obese individuals or in normal-weight subjects. As compared with previously shown prevalence ratios (computed by Poisson regression), prevalence ratios estimated from logistic models were slightly larger (Web Table 2 ).
The sum of concentrations of the 6 POPs tended to increase as the number of cardiometabolic abnormalities increased (P trend = 0.001) (Web Figure 1) . The association was similarly observed among normal-weight and overweight/obese individuals.
The prevalence of MetS was 25.2% (216 of 858 participants) when using the IDF definition and 23.0% (203 of 881) when using the ATPIII definition (Web Table 3 ). Adjusted prevalence ratios of having MetS according to POP concentrations are shown in Figure 2 
DISCUSSION
Metabolically healthy individuals-obese, overweight, or normal weight-had significantly lower serum concentrations of POPs than individuals with 2 or more cardiometabolic abnormalities. In obese/overweight individuals and normal-weight individuals, lower concentrations of HCB, β-HCH, and PCBs were also generally associated with a healthy metabolic phenotype even when adjusting for age, sex, BMI, cigarette smoking, alcohol consumption, physical activity, occupational social class, and education. The magnitude of the associations was stronger in normal-weight individuals than in the obese/overweight. The sum of orders of the 6 POPs individually associated with metabolic phenotypes and the sum of orders of all 8 POPs showed linear dose-response relationships among normal-weight individuals and were also associated with the metabolic phenotype in obese/overweight individuals.
Similarly, a positive linear association was observed between the sum of POP concentrations and the number of cardiometabolic abnormalities. Thus, the observed POP-metabolic phenotype relationship appears to be independent of the cutoff number of abnormalities used to classify the unhealthy phenotype. Multiple criteria have been applied to define metabolic phenotypes (1, 2, 37); we used information on not just the components of MetS but also on homeostatic model assessmentmeasured insulin resistance and inflammation, which are some of the possible mechanisms of action or effects of POPs along with endocrine disruption (9, 13, 16) . POPs might also increase the risk of obesity (38) , the main risk factor for unhealthy metabolic phenotypes, and they have also been associated with an increased risk for some of the cardiometabolic abnormalities considered when defining the unhealthy phenotype, such as hyperglycemia or hypertension (9, 14, 17) . . Differences between pairs of medians were all statistically significant (P < 0.001 for all except for p,p′-DDT: P = 0.013 for normal-weight and 0.027 for overweight/obese participants; Mann-Whitney U test, 2-tail). DDE, dichlorodiphenyldichloroethene; DDT, dichlorodiphenyltrichloroethane; HCB, hexachlorobenzene; HCH, hexachlorocyclohexane; PCB, polychlorinated biphenyl. To our knowledge, only 2 studies have analyzed associations between POP concentrations and metabolic phenotypes, and these studies did not include normal-weight individuals. Our results agree with Gauthier et al. (22) and Dirinck et al. (23) , who reported positive associations between PCB concentrations and unhealthy metabolic phenotypes in overweight and obese individuals. Remarkably, we also observed the association in normal-weight individuals. The lack of association that the first study to analyze associations of DDT, HCB, and β-HCH with metabolic phenotypes (including C-reactive protein and homeostatic model assessment). It is also the first report on the relationship between POP concentrations and metabolic phenotypes in a sample of the general population. In contrast with previous studies, ours included diabetic and nondiabetic individuals, both sexes, a wide age range, and a much larger number of individuals. Our observation that in normal-weight participants the association with the unhealthy metabolic phenotype was stronger with PCB concentrations in the third quartile than in the fourth quartile is coherent with evidence that endocrine-disrupting chemicals such as POPs can have nonmonotonic effects (10, 39) . Some previous studies of POPs also reported nonmonotonic associations with outcomes as type 2 diabetes and MetS (9, 10, 14, 19, 39, 40) . However, confirmation of the nonlinear doseresponses in larger populations is needed.
Our results agree with previous studies that also found positive associations between PCBs and some organochlorine pesticides, such as β-HCH, and MetS (18-21), but not with DDT and DDE (20) . In a prospective nested case-control study based on the general population in Korea (with 64 cases of MetS and 182 controls followed during 4 years), serum concentrations of PCBs and organochlorine pesticides at baseline were associated with an increased risk of MetS (19) . Although random sampling variation cannot be discarded, the different results for specific POPs might reflect different mechanisms of action or different target organs. The main limitation of our study is its cross-sectional design, which prevents inferring causal relationships: Theoretically, individuals who developed an unhealthy metabolic phenotype might have accumulated POPs at a higher rate than individuals who retained a healthy phenotype. However, empirical evidence in support of such possibility is scant, and the putative mechanisms have not been elucidated; for example, few if any human studies have shown that the underlying pathophysiological processes that eventually lead to clinical type 2 diabetes or other metabolic disorders also induce a higher accumulation of POPs (10) . Furthermore, the study findings are in accordance with results of experimental animal studies (10, 13, 16 ) and human prospective studies (9, 10, 14, 15, 19) , which were able to rule out "reverse causation" and disease progression bias. Also because of its cross-sectional design, and because dyslipidemia was one of the abnormalities considered when defining phenotypes, lipid correction of POP concentrations would entail an overadjustment (31) . A relatively high number of comparisons were made; hence, false positives might have occurred. Nonetheless, associations with the unhealthy phenotype were largely consistent for normal-weight and overweight/obese individuals and for groups of highly correlated compounds (for example, among PCBs). Study limitations also included the lack of information on changes in body weight (23) and the use of capillary blood instead of venous blood to define hyperglycemia (26) .
Our findings support the hypothesis that exposure to POPs is associated with unhealthy metabolic phenotypes, not only in obese and overweight individuals but also in normal-weight individuals. POPs might also contribute to increase the risk of MetS. These results should be refuted or confirmed by prospective longitudinal studies assessing a larger number of potentially obesogenic environmental and individual factors. Nevertheless, they add to the existing evidence supporting policies to decrease human exposure to POPs (12, 41, 42) . Considering that, in the majority of the general population, POP exposure occurs largely through the ingestion of fatty parts of animal foods (43) (44) (45) , results might also support existing dietary guidelines to prevent cardiometabolic disorders.
